Here we review the clinical and translational implications of the caveolin gene family for understanding the pathogenesis of human diseases, including breast and prostate cancers, pulmonary hypertension, cardiomyopathy, diabetes, and muscular dystrophy. Detailed phenotypic analysis of caveolin knockout mice has served to highlight the crucial role of a caveolin deficiency in the pathogenesis of many human disease processes. Mutations in the human caveolin genes are associated with a number of established genetic disorders (such as breast cancer, lipodystrophy, muscular dystrophy, and cardiomyopathy), making the caveolins important and novel targets for drug development. The implementation of new strategies for caveolin replacement therapy-including caveolin mimetic peptides-is ongoing. Caveolins are the signature proteins of specialized invaginations of the plasma membrane, named caveolae, that function to regulate signal transduction within the cell. Three members of the caveolin family have been identified, caveolin-1 (Cav-1), -2 (Cav-2), and -3 (Cav-3). Cav-1 and -2 are coexpressed in a wide range of tissues, whereas Cav-3 is muscle specific. The generation of caveolin null mice has demonstrated clear functions for the caveolin proteins in mammalian physiology. Cav-1 null mice present several pathological phenotypes, suggesting that Cav-1 has pleiotropic functions in various organs. Cav-1 null mice show increased susceptibility towards the development of epidermal and mammary tumors, but exhibit decreased tumor formation in the prostate, demonstrating that Cav-1 behaves as a tumor suppressor or a tumor promoter depending on the cellular context. Moreover, several other phenotypes of Cav-1 null mice indicate that Cav-1 is important in the regulation of insulin signaling, and in pulmonary and cardiac function.
Caveolins are the signature proteins of specialized invaginations of the plasma membrane, named caveolae, that function to regulate signal transduction within the cell. Three members of the caveolin family have been identified, caveolin-1 (Cav-1), -2 (Cav-2), and -3 (Cav-3). Cav-1 and -2 are coexpressed in a wide range of tissues, whereas Cav-3 is muscle specific. The generation of caveolin null mice has demonstrated clear functions for the caveolin proteins in mammalian physiology. Cav-1 null mice present several pathological phenotypes, suggesting that Cav-1 has pleiotropic functions in various organs. Cav-1 null mice show increased susceptibility towards the development of epidermal and mammary tumors, but exhibit decreased tumor formation in the prostate, demonstrating that Cav-1 behaves as a tumor suppressor or a tumor promoter depending on the cellular context. Moreover, several other phenotypes of Cav-1 null mice indicate that Cav-1 is important in the regulation of insulin signaling, and in pulmonary and cardiac function.
Cav-2 null mice reveal unique functions of Cav-2 in the lung and in the skeletal muscle. Indeed, Cav-2 null mice show lung defects with increased alveolar septal thickness and fibrosis, and exhibit a peculiar skeletal muscle phenotype, with tubular aggregate formation and mitochondrial proliferation. Cav-3 null mice exhibit pathological changes in the skeletal muscle and the heart, and show an unexpected metabolic phenotype, with increased adiposity and insulin resistance.
Importantly, data from human samples confirm that caveolins are involved in human pathology. Mutations in the Cav-1 gene are found in breast cancer as well as in oral squamous-cell carcinomas. Cav-1 mutations are associated exclusively with estrogen receptor (ER-a)-positive breast tumors, suggesting that Cav-1 normally regulates ER expression and signaling. Mutations in the Cav-3 gene are detected in a wide spectrum of skeletal muscle disorders, including limb girdle muscular dystrophy, distal myopathy, idiopathic hyperCKemia, rippling muscle disease, as well as in cardiac pathologies such as familial hypertrophic cardiomyopathy, long-QT congenital syndrome (LQTS), and sudden infant death syndrome (SIDS).
Thus, modulation of caveolin expression may represent a novel therapeutic approach for the treatment of a number of pathological conditions. Preliminary studies have shown that a Cav-1 mimetic peptide may be successfully used for the treatment of cancer and of pulmonary hypertension (PH). More studies will be required to evaluate the possibility of using Cav-1 mimetic peptides in other pathological contexts.
CAVEOLAE AND THE CAVEOLIN GENE FAMILY
Caveolae are 50-100 nm O-shaped invaginations of the plasma membrane. Owing to their high content of cholesterol, glycosphingolipids, and sphingomyelin, caveolae are considered a specialized subset of detergent-insoluble plasma membrane microdomains, named lipid rafts. 1 The signature proteins of caveolae are a family of proteins called caveolins. 2 Structurally, the formation of caveolae requires the capability of caveolin to bind cholesterol and to oligomerize (Figure 1) . [3] [4] [5] Three members of the caveolin family have been discovered so far.
Cav-1 is widely expressed and is most abundant in adipocytes, fibroblasts, endothelial cells, as well as epithelial cells such as mammary epithelial cells and type I pneumocytes. 6 Cav-1 is essential for caveolae formation, and Cav-1 expression levels correlate with caveolae numbers. 7, 8 Cav-2 is expressed in the same cell types as Cav-1.
9,10 Cav-3 is the muscle-specific family member and is mainly found in heart, skeletal muscle, as well as smooth muscle cells (SMC). 11 Caveolins are more than just caveolae-associated proteins. They help drive the formation of a microenvironment to compartmentalize several signaling molecules, thereby facilitating the cross talk between different signaling pathways. 12 The caveolin-scaffolding domain (CSD) serves as a docking site for the binding and tonic inhibition of several classes of signaling molecules belonging to proproliferative and prosurvival pathways. Thus, deregulation of caveolin expression and function is involved in many pathological conditions. The physiological implications of caveolins Figure 1 Caveolin domain organization, membrane topology, oligomerization, and caveolar assembly. This diagram summarizes the domain organization of a caveolin-1 monomer, its self-oligomerization into caveolar assembly units, and the integration of these assembly units into a caveolar membrane domain. The cytoplasmic surface of the caveolar coat provides an 'integrated scaffold' onto which various classes of signaling molecules can assemble at the plasma membrane, such as G proteins, Src-family tyrosine kinases, endothelial nitric oxide synthase (eNOS), and components of the Ras-p42/44-MAP kinase cascade. Caveolae organelles also function as docking sites for many different classes of cell-surface receptors, including G-protein-coupled receptors, cytokine receptors, and receptor tyrosine kinases. 13 In soft agar, the anchorageindependent growth of transformed cells can be reversed by Cav-1 re-expression. 14, 15 In NIH-3T3 cells, antisensemediated downregulation of endogenous Cav-1 induces anchorage-independent growth, promotes tumor formation in nude mice with hyperactivation of the MAP kinase pathway. 16 Importantly, loss of Cav-1 in mice was shown to promote cellular growth in several contexts, including the mammary gland and the skin. For example, although the ablation of Cav-1 is not sufficient to induce spontaneous tumor formation, Cav-1 null mammary glands display cellular hyperplasia, and accelerated mammary gland development during pregnancy. 17, 18 In the MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen) mouse model background, loss of Cav-1 accelerates dysplastic lesion formation, promotes premature development of mammary tumors, and increases metastatic potential. 19, 20 In addition, the combined loss of INK4a, a tumor suppressor, and Cav-1 leads to severe mammary hyperplasia with increased side branching and fibrosis. 21 In the skin, Cav-1(À/ À) mice demonstrate hypersensitivity to carcinogen-induced epidermal tumors. Following 16 weeks of treatment with the carcinogen DMBA, Cav-1(À/À) null mice show very significant increases in tumor incidence, tumor area, and tumor number per mouse when compared to wild-type (WT) counterparts. 22 Mechanistically, in the mammary gland and in the skin, Cav-1 is thought to inhibit proliferation and cellular growth. Indeed, in the context of Cav-1 genetic ablation, carcinogen-induced epidermal tumors and oncogene-induced mammary tumors show hyperactivation of the mitogenic p42/44-MAP kinase pathway, with increased levels of cyclin D1. 20, 22 However, Cav-1 does not behave as a tumor suppressor in all cellular contexts. A growing body of evidence derived from cellular, mouse, and human studies clearly indicates that Cav-1 acts as a tumor promoter in other organs, such as the prostate. In the TRAMP (transgenic adenocarcinoma of mouse prostate) mouse model of prostate cancer, Cav-1 expression is increased when compared to the normal prostate epithelium. 23 Genetic ablation of Cav-1 in TRAMP mice decreases incidence of prostate tumors at 28 weeks of age and reduces metastasis to regional lymph node and to distant organs, such as the lungs. 23 In patients with prostate cancer, Cav-1 expression is increased in 13% of well-differentiated tumors, 24% of moderately differentiated tumors, and 39% of poorly differentiated tumors. 24 These results suggest that Cav-1 overexpression in prostate cancer cells correlates with tumor progression. 24 Other studies have shown that high levels of Cav-1 are associated with high Gleason's score, reduced survival, and poor prognosis in prostate cancer. 25, 26 Finally, a higher incidence of Cav-1 positivity is observed in metastatic lesions and metastasis-derived cell lines, as compared to primary tumors and primary tumor-derived cell lines, respectively. 27 In the mammary gland and skin, Cav-1 negatively regulates proliferation. However, the antiapoptotic properties of Cav-1 seem to contribute to the development of prostate cancer. Prostate tumors derived from TRAMP/Cav-1 null mice exhibit increased apoptosis as assessed by TUNEL staining, with increased levels of prostate apoptosis response factor-4 (PAR-4) and PTEN. 23 However, the function of Cav-1 in apoptosis in other cell types still remains largely unexplored and highly debated. In prostate cancer cells, it is believed that Cav-1 can shift from its conventional membrane-bound position to a secreted form outside the cell. Indeed, Cav-1 has been detected in the serum of patients with prostate cancer. 28 It was also found that the secreted form of Cav-1 is bioactive as it could promote cell survival. 28 The phosphorylation of Cav-1 on serine 80 seems to be involved in the conversion of Cav-1 from a membrane protein to a secreted form.
29 Table 1 summarizes the main phenotypes of Cav-1(À/À) mice and their implications in different human pathologies.
CAV-1 AND ADULT STEM CELLS
Studies have shown that Cav-1 may normally regulate the proper differentiation of stem/progenitor cell populations in organs, such as the skin, the mammary gland, and the intestine, that are physiologically subjected to constant selfrenewal ( Figure 2 ). For example, Cav-1 deficiency leads to an amplification of an adult mammary stem cell population, both in vivo and in vitro. The expression of stem cell markers, such as Sca-1 and keratin 6, is greatly increased in the hyperplastic mammary ducts of Cav-1-deficient mice, as well as in 3D cultures of Cav-1(À/À) primary mammary epithelial cells. Such an amplification of progenitor cells is functionally associated with the abnormal presence of myoepithelial cells in the hyperplastic lesions of Cav-1-deficient mammary glands. 32 In addition, genetic ablation of Cav-1 induces an abnormal amplification of small intestine crypt stem cells, resulting in increased susceptibility to g-radiation. Cav-1 null small intestine crypt stem cells display higher proliferation rates, as compared to WT controls. Because of its fast renewing nature, the small intestine constitutes one of the main targets of radiation. After g-radiation exposure, Cav-1-deficient mice display a decreased survival rate, as compared to WT mice. 30 Mechanistically, Wnt/b-catenin signaling, which normally controls stem cell self-renewal, is upregulated in Cav-1 null mammary and crypt stem cells. The longevity and slowdividing properties of stem cells facilitate the accumulation 
CAV-1: INSULIN SIGNALING, PULMONARY AND CARDIAC FUNCTION, AND ISCHEMIA
The analysis of Cav-1(À/À) mice has highlighted how the loss of Cav-1 function may lead to a number of important pathological conditions. In addition to its involvement in breast, skin, and prostate cancer, Cav-1 is also important in diabetes, lung and heart diseases, and ischemia (Table 1) .
Cav-1, Insulin Signaling, and Diabetes Cav-1(À/À) mice show resistance to diet-induced obesity, and display adipose tissue atrophy. 33 Metabolically, plasma levels of insulin and glucose are normal in Cav-1 null mice. 33 However, an insulin tolerance test revealed abnormally low glucose uptake in young Cav-1(À/À) mice, suggestive of impaired insulin signaling. 34 This defect in glucose uptake is due to a severe deficiency of insulin receptor protein expression in Cav-1(À/À) adipose tissue. 34 In direct support of these findings, Cav-1 null adipose tissue displays decreased insulin signaling, as assessed by phosphorylation of insulin receptor and its downstream targets. 34 Although loss of Cav-1 is not sufficient to induce diabetes, it may function as a predisposing factor for the development of insulin resistance in humans.
Cav-1 and Pulmonary Function
Cav-1 is highly expressed in the lung, and is found in several pulmonary cell types, including endothelial cells and pneumocytes. Histological analysis of Cav-1 null mice reveals a deeply modified lung morphology with reduced alveolar spaces, increased wall thickening, fibrosis, and hypercellularity. 35, 36 In addition, Cav-1 null mice develop PH. 37, 38 Reduced Cav-1 levels in the lung have been documented in several animal models of PH and in patients with severe PH. These findings may have important implications for understanding human respiratory pathologies, such as PH, fibrosis, as well as acute respiratory syndrome.
Cav-1 and Cardiovascular Function
Cav-1 is implicated in several cardiovascular pathologies, including cardiac hypertrophy, neointima formation and atherosclerosis. Cardiac hypertrophy is a critical pathology leading to heart failure. Cav-1(À/À) mice show progressive concentric left ventricular hypertrophy, as well as right ventricular dilation. 37, 39 Cav-1 expression is restricted to the supporting cells of the heart, such as fibroblasts and endothelial cells. Excessive activation of the Ras-p42/44-MAP kinase cascade in Cav-1(À/À) cardiac fibroblasts is considered one of the upstream key factors promoting Caveolin genes and disease pathogenesis I Mercier et al hypertrophy and fibrosis in the adjacent myocytes. 40 Notably, Cav-1(À/À) cardiac fibroblasts exhibit p42/44 MAP kinase hyperactivation when compared to WT fibroblasts, 39 suggesting that the hypertrophy of Cav-1 null hearts occurs through a paracrine mechanism.
Neointimal hyperplasia is the principal cause for clinical failures in angioplasty and is a critical component of restenosis. During the development of neointimal hyperplasia, the arterial wall thickens and the lumen narrows as a consequence of SMC accumulation and proliferation in the intima. 41, 42 Genetic ablation of Cav-1 in mice facilitates SMC proliferation and neointima formation. At 4 weeks after ligation, Cav-1(À/À) carotid arteries showed significantly more neointimal hyperplasia with subtotal luminal occlusion, as compared to WT mice. Mechanistically, the development of neointimal hyperplasia in Cav-1(À/À) mice is mediated by elevated levels of phospho-p42/44 MAP kinase and cyclin D1. . Reproduced with permission from Capozza et al, 22 Williams et al, 31 and Li et al.
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Caveolin genes and disease pathogenesis I Mercier et al Atherosclerosis is characterized by the accumulation of modified lipoproteins in the subendothelial space followed by the recruitment and proliferation of monocytes/macrophages and SMC. Genetic ablation of Cav-1 in mice confers protection against atherosclerosis. In the apolipoprotein-Edeficient (ApoEÀ/À) atherogenic mouse model background, loss of Cav-1 prevents the development of aortic atheromas, with an B70% reduction in atherosclerotic lesion area. Mechanistically, loss of Cav-1 is associated with the downregulation of proatherogenic molecules, namely CD36 and vascular cell adhesion molecule-1 (VCAM-1). 44 Thus, Cav-1(À/À) mice are more sensitive to the development of neointimal hyperplasia (luminal narrowing), but are strongly resistant to the development of atheromas, clearly demonstrating the different pathophysiology of subendothelial vs mural narrowing of the arterial lumina.
Cav-1 and Ischemia
Recent studies have directly addressed the functional role of Cav-1 in ischemic injury. First, Cav-1 ablation in mice was shown to promote ischemic injury in a model of hindlimb ischemia. 45 Similarly, in a model of cerebral artery occlusion, Cav-1 null mice display a significant increase in the volume of cerebral infarcts, as compared to WT mice. Mechanistically, Cav-1 null ischemic brains exhibited decreased proliferation of endothelial cells and an elevated apoptotic index, as compared to WT counterparts. 46 Ischemic preconditioning has previously been shown to increase the cardiac phosphorylation of Cav-1 and SRC in mice subjected to myocardial ischemia reperfusion. These interesting observations suggest that phosphorylation of Cav-1 and SRC might have a cardioprotective role in ischemic injuries. Hence, genetic ablation of the Cav-1 gene in mice was shown to attenuate the protective effect of myocardial ischemic preconditioning. 47 
CAVEOLIN-2: PULMONARY AND SKELETAL MUSCLE FUNCTIONS
Cav-2 requires the presence of Cav-1 for stabilization and membrane targeting, such that in the absence of Cav-1, Cav-2 is retained in the endoplasmic reticulum/Golgi complex and undergoes degradation through a proteasomal pathway. 48, 49 As a consequence, Cav-2 expression is nearly abrogated in Cav-1 null mice. 35, 36 Thus, Cav-2 was considered an 'accessory' protein that functions in conjunction with Cav-1. However, the generation and analysis of Cav-2 null mice revealed unique functions for Cav-2 in the physiology of the lung and of the skeletal muscle. Cav-2 null mice show normal caveolae formation and nearly normal levels of Cav-1 expression. 50 Cav-2 null lungs show thickened alveolar septa with increased number of endothelial cells. Consequently, Cav-2 null mice show exercise intolerance, suggestive of an impaired gas exchange that is often associated with human pulmonary diseases. 50 Interestingly, the Cav-2 null lung phenotypes are identical to the ones observed in Cav-1 null mice. 35, 36 Because Cav-2 expression is severely reduced in Cav-1 null mice, a Cav-2 deficiency is considered to be the root cause of this lung disorder.
Cav-2 null mice also exhibit an unexpected skeletal muscle phenotype. Cav-2 null skeletal muscles show peculiar abnormalities, such as tubular aggregate formation, and mitochondrial proliferation/aggregation. In addition, Cav-2 deficiency induces increased numbers of satellite cells, which are skeletal muscle-specific stem/precursor cells. 51 For a summary of Cav-2 null mice phenotypes and their implications in human pathologies, please refer to Table 2 .
CAVEOLIN-3: SKELETAL MUSCLE DISORDERS, HEART DISEASE, AND DIABETES
Caveolin-3 is the muscle-specific family member, and is necessary for caveolae formation in muscle tissues. Indeed, electron microscopy revealed a lack of caveolae in all striated and cardiac muscle cells of Cav-3 null mice. 52, 53 Cav-3 null skeletal muscle shows signs of mild myopathic changes, such as mononuclear cell infiltration, variable fiber size, and presence of necrosis. These phenotypes are similar to the ones found in a human disease, termed limb-girdle muscular dystrophy (LGMD-1C), which is due to mutations in the Cav-3 gene.
A Cav-3 deficiency also affects cardiac function, with the development of cardiac hypertrophy, dilatation, and reduced fractional shortening at 4 months of age. 54 Cav-3 null cardiac myocytes show hypertrophy, with cellular infiltrates and progressive interstitial and perivascular fibrosis. Hyperactivation of the Ras-p42/44-MAP kinase pathway is associated with these cardiac phenotypes. 54 Interestingly, transgenic overexpression of either WT or dominant-negative mutant Cav-3 was shown to induce cardiomyopathy, with cardiac tissue degeneration, and reductions in cardiac functions. 55, 56 These results suggest that maintenance of normal Cav-3 expression levels is essential for proper cardiac function.
Surprisingly, Cav-3 null mice also show an interesting metabolic phenotype. Cav-3 null mice demonstrate increased adiposity and develop insulin resistance, as shown by decreased glucose uptake and reduced glucose metabolic flux in their skeletal muscles. During fasting, Cav-3 null skeletal muscles exhibit normal insulin receptor protein levels. However, insulin stimulation induces a severe reduction in insulin receptor levels in Cav-3 null mice, suggesting that Cav-3 may function to stabilize insulin receptor. These results show that Cav-3 contributes to the regulation of whole body glucose metabolism in vivo and indicates that Cav-3 may be involved in the development of insulin resistance. 57, 58 For a summary of Cav-3 null mouse phenotypes and their implications in human pathologies, please refer to Table 2 .
CAVEOLIN MUTATIONS IN HUMAN DISEASE
Over the past few years, mutations in the caveolin genes have been detected in several types of human diseases, clearly indicating the importance of these proteins for normal human physiology, and demonstrating that dysregulation of caveolin function is a critical factor for the development of human disease.
Cav-3 Mutations
The first mutations in a caveolin gene were identified a decade ago, when mutations in the Cav-3 gene were found in patients with LGMD-1C. 59 Since then, several other mutations have been found in patients with skeletal muscle disorders. The spectrum of disease phenotypes associated with Cav-3 mutations is quite variable, ranging from LGMD-1C to idiopathic hyperCKemia, rippling muscle disease, and distal myopathy. For a comprehensive review of Cav-3 and muscle disorders, please consult the GeneReview database available at http://www.genetests.org (search CAV3). Most of the Cav-3 mutations are heterozygous and cause a dramatic decrease in Cav-3 expression in skeletal muscle, thus acting in a dominant-negative manner. 60 Finally, mutations in the Cav-3 gene have been found in familial hypertrophic cardiomyopathy, 61 in the arrhythmogenic syndrome LQTS, 62 as well as in SIDS. 63 
Cav-1 Mutations
Somatic mutations in the Cav-1 gene are involved in human cancer. We and others have shown that a proline to leucine substitution at position 132 (P132L) in the Cav-1 gene is found in 16-20% of breast cancers. 64, 65 This heterozygous mutation acts in a dominant-negative manner and induces the intracellular retention of the normal Cav-1 protein at the level of the ER-Golgi complex. 17 Other mutations were also found in human breast cancer samples, such as W128stop, Y118H, S136R, I141T, Y148H, and Y148S. 65 Most interestingly, Cav-1 mutations only correlate with ER-a (ER-a)-positive breast tumors, and are found in up to 35% ER-apositive tumors. 65 These results suggest that Cav-1 may regulate ER-a expression. In fact, we have shown that ER-a is dramatically upregulated in the luminal mammary epithelial cells of Cav-1 knockout mice (KO), as compared to their WT counterparts. 65 Because ER-a expression increases as mammary cell transformation progresses, these results suggest that Cav-1 mutations may be an initiating event in the development of human breast cancers. Thus, screening of patient biopsies for Cav-1 mutations could become a routine analysis as a preventive measure to detect estrogen-dependent breast cancer at an early stage. These findings provide new insights into the regulation of ER-a in breast cancer. Finally, mutations and abnormal expression of Cav-1 have been identified in human oral squamous-cell carcinomas. 66 Recently, a homozygous mutation in the Cav-1 gene has been detected in Berardinelli-Seip congenital lipodystrophy, a rare genetic disorder characterized by near absence of adipose tissue, severe dyslipidemia, and insulin resistance. This mutation induces a complete loss of Cav-1 expression in skin fibroblasts. 67 These findings provide human genetic evidence to directly support a critical role for Cav-1 in regulation of adipocyte function and insulin signaling. Additional heterozygous Cav-1 mutations have now been observed in patients with atypical partial lipodystrophy and hypertriglyceridemia. 68 See Garg and Agarwal, 69 for a recent review on this subject. 70 After subcutaneous implantation of Lewis lung carcinoma cells (LLC), the injection of the CSD peptide reduced tumor size and tumor vascular permeability, and increased tumor necrosis, suggesting that Cav-1 prevents tumorigenesis by affecting tumor blood supply. 70 Similar experiments in WT and Cav-1(À/À) mice further demonstrated the involvement of Cav-1 in vascular permeability and tumor development. In Cav-1 KO mice, LLC-derived tumors showed significantly higher growth rates, with increased angiogenesis and decreased apoptosis than tumors implanted in WT hosts. Most interestingly, administration of CSD peptide was able to reverse tumor hyperpermeability as well as to attenuate the increased tumor growth. 71 Therapeutic administration of the Cav-1 scaffolding domain peptide has been used in other experimental models. Indeed, administration of CSD peptide has been successfully used to prevent the development of PH, right ventricular hypertrophy, and pulmonary artery medial hypertrophy in a monocrotaline-induced PH rat model. 72 Administration of CSD peptide to monocrotaline-treated rats significantly prevented PH and normalized pulmonary artery medial hypertrophy and right ventricular hypertrophy. 72 Finally, in an experimental mouse model of inflammation, the administration of the CSD peptide has also been shown to decrease inflammation, reduce edema formation and vascular permeability. 73 Thus, the administration of Cav-1 peptide mimetics might become a novel alternative treatment for cancer as well as PH patients.
FUTURE DIRECTIONS: ROLE OF CAVEOLINS IN THE CANCER STROMA
Normal epithelial cells are often surrounded by fibroblasts that serve mainly as support to protect the tissue from damage. Fibroblasts can proliferate and secrete extracellular matrix (ECM) proteins as a response to injury. Once the wound-healing process is complete, they undergo apoptosis and the ECM production lessens. Several lines of evidence now suggest that stromal fibroblasts become 'activated' and have a very dynamic role in tumor initiation and progression. These cancer-associated fibroblasts (CAFs) express smooth muscle actin, have contractile functions, and secrete ECM proteins. Unlike normal fibroblasts involved in wound repair, these CAFs do not undergo spontaneous apoptosis, rather they remain activated and hyperproliferate. Studies suggest the recruitment of CAFs is not only a secondary event to tumor initiation, but is very dynamic as CAFs can increase the growth of adjacent epithelial cells through paracrine mechanisms. For a complete review on stromal fibroblasts and cancer please see Kalluri and Zeisberg. 74 However, very little is known about the mechanism(s) controlling the proliferation of CAFs and their clinical implications in cancer progression and outcome. Recently, it was shown that Cav-1 protein expression is decreased in primary cultures of CAFs isolated from patients with invasive breast cancer and that loss of Cav-1 function might be involved in their hyperproliferation. 75 Accordingly, treatment of these cells with a cellpermeable Cav-1 mimetic peptide decreased the phosphorylation of retinoblastoma protein (RB) as well as proliferating cell nuclear antigen (PCNA) and MCM7 (minichromosome maintenance) proteins levels, two RB/E2F target proteins. Therefore, caveolin proteins might be important in cancer through their novel 'tumor suppressor' function in the neoplastic stroma (Figure 3 ).
In accordance with this idea, we have recently shown that loss of stromal Cav-1 is a novel breast cancer biomarker that predicts early disease recurrence, metastasis, survival, and tamoxifen resistance. 76 For example, lymph-node-positive breast cancer patients showed an B11.5-fold reduction in 5-year progression-free survival in the absence of stromal Cav-1 (80 vs 7% survival). 76 Mechanistically, this appears to be related to the idea that the loss of Cav-1 expression in mammary fibroblasts leads to pRB inactivation, increased growth factor secretion, and stromal angiogenesis 77, 78 ( Figure 3 ). As such, breast cancer patients lacking stromal Cav-1 might greatly benefit from antiangiogenic therapy, in addition to standard treatment regimens. Thus, future studies are warranted to explore this novel function for caveolins in the stromal pathogenesis of human cancers.
